Innovent Biologics, Inc. (IVBXF)
OTCMKTS · Delayed Price · Currency is USD
11.45
+0.09 (0.75%)
At close: Feb 11, 2026
Innovent Biologics Revenue
Innovent Biologics had revenue of 5.95B CNY in the half year ending June 30, 2025, with 120.36% growth. This brings the company's revenue in the last twelve months to 11.42B, up 53.18% year-over-year. In the year 2024, Innovent Biologics had annual revenue of 9.42B with 51.82% growth.
Revenue (ttm)
11.42B CNY
Revenue Growth
+53.18%
P/S Ratio
12.48
Revenue / Employee
1.85M CNY
Employees
6,190
Market Cap
19.90B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
| Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
| Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
| Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
| Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |
Innovent Biologics News
- 2 days ago - Hong Kong stocks extend bounce-back from tech turbulence as risk sentiment returns - South China Morning Post
- 3 days ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 3 days ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 3 days ago - Hong Kong stocks start week strong on sentiment stabilisation, Japan election - South China Morning Post
- 3 days ago - Innovent And Lilly Expand Collaboration To Advance Global Oncology & Immunology Drugs - Nasdaq
- 3 days ago - Innovent Biologics (IVBIY) Expands Partnership with Eli Lilly for Cancer Drug Development - GuruFocus
- 3 days ago - Eli Lilly expands partnership with Innovent to develop oncology, immunology drugs - Seeking Alpha
- 3 days ago - Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology - PRNewsWire